EchoGo® Heart Failure vs Tempus ECG-AF
Similar category, different focus. These tools serve overlapping but distinct needs.
Comparability 60/100
Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
AI Verdict
Tool A (EchoGo® Heart Failure) is designed for the diagnosis of HFpEF using echocardiograms, providing rapid insights for clinical decisions. In contrast, Tool B (Tempus ECG-AF) utilizes 12-lead ECGs to predict the risk of new-onset atrial fibrillation in older patients. While both are cardiology AI solutions, their distinct input modalities and target cardiac conditions make them complementary rather than direct competitors.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Frequently Asked Questions
EchoGou00ae Heart Failure is designed to analyze routine echocardiograms to detect Heart Failure with preserved Ejection Fraction (HFpEF), providing insights to support clinical decisions. Tempus ECG-AF is an AI-based algorithm that analyzes 12-lead ECG recordings to identify patients aged 65 or older at increased risk of developing atrial fibrillation/flutter (AF) within the next 12 months.
EchoGou00ae Heart Failure analyzes routine echo video clips, integrating seamlessly with existing workflows and IT stacks. Tempus ECG-AF requires 12-lead ECG recordings and is compatible with FDA-authorized resting 12-lead ECGs from GE Medical Systems and Philips Medical Systems.
EchoGou00ae Heart Failure is intended for use in patients undergoing routine echocardiograms for HFpEF detection. Tempus ECG-AF is specifically for patients aged 65 or older who do not have pre-existing AF, pacemakers, ICDs, or recent cardiac surgery, to assess their risk of developing AF within 12 months.
EchoGou00ae Heart Failure is reimbursable via CPT code 0932T for outpatient analysis, with a national Medicare average of $316 per analysis, effective January 1, 2025. Tempus ECG-AF has CMS reimbursement available via CPT codes 0764T and 0765T to APC 5734, with a Medicare rate of $128.90, also effective January 1, 2025.
EchoGou00ae Heart Failure provides insights within 20 minutes of analyzing routine echo video clips, delivering automated structured reports. The provided information for Tempus ECG-AF does not specify a turnaround time for results, but it analyzes existing 12-lead ECG recordings.
EchoGou00ae Heart Failure is clinically validated with 90% sensitivity and 86% specificity for HFpEF, trained on over 10 years of outcome data. Tempus ECG-AF was trained on over 1.5 million ECGs from over 500,000 patients.